Overview

Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS

Status:
Active, not recruiting

Trial end date:
2022-06-30

Target enrollment:

Participant gender:

Summary

To characterize the safety and tolerability of 1) MBG453 as a single agent or in combination with PDR001 or 2) PDR001 and/or MBG453 in combination with decitabine or azacitidine in AML and intermediate or high- risk MDS patients, and to identify recommended doses for future studies.

Phase:

Phase 1

Details

Lead Sponsor:

Novartis Pharmaceuticals

Treatments:

Azacitidine
Decitabine
Spartalizumab